An Invitation to Open Innovation in Malaria Drug Discovery: 47 Quality Starting Points from the TCAMS

被引：62

作者：

Calderon, Felix ^{[1
]}

Barros, David ^{[1
]}

Maria Bueno, Jose ^{[1
]}

Miguel Coteron, Jose ^{[1
]}

Fernandez, Esther ^{[1
]}

Javier Gamo, Francisco ^{[1
]}

Luis Lavandera, Jose ^{[1
]}

Luisa Leon, Maria ^{[1
]}

Macdonald, Simon J. F. ^{[2
]}

Mallo, Araceli ^{[1
]}

Manzano, Pilar ^{[1
]}

Porras, Esther ^{[1
]}

Maria Fiandor, Jose ^{[1
]}

Castro, Julia ^{[1
]}

机构：

[1] GlaxoSmithKline, DDW, Tres Cantos 28760, Spain

[2] MMV, CH-1215 Geneva 15, Switzerland

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2011年 / 2卷 / 10期

关键词：

Malaria; TCAMS; lead optimization; open innovation; PLASMODIUM-FALCIPARUM;

D O I：

10.1021/ml200135p

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

In 2010, GlaxoSmithKline published the structures of 13533 chemical starting points for antimalarial lead identification. By using an agglomerative structural clustering technique followed by computational filters such as antimalarial activity, physicochemical properties, and dissimilarity to known antimalarial structures, we have identified 47 starting points for 13,533 2948 lead optimization. Their structures are provided. We invite potential collaborators to work with us to discover new clinical candidates.

引用

页码：741 / 746

页数：6

共 50 条

[41] Open data for drug discovery: learning from the biological community
Hersey, Anne
Senger, Stefan
Overington, John P.
[J]. FUTURE MEDICINAL CHEMISTRY, 2012, 4 (15) : 1865 - 1867
[42] Application of a phenotypic drug discovery strategy to identify biological and chemical starting points for inhibition of TSLP production in lung epithelial cells
Orellana, Adelina
Gonzalez, Vicente Garcia
Lopez, Rosa
Pascual-Guiral, Sonia
Lozoya, Estrella
Diaz, Julia
Casals, Daniel
Barrena, Antolin
Paris, Stephane
Andres, Miriam
Segarra, Victor
Vilella, Dolors
Malhotra, Rajneesh
Eastwood, Paul
Planaguma, Anna
Miralpeix, Montserrat
Nueda, Arsenio
[J]. PLOS ONE, 2018, 13 (01):
[43] Innovation and greater probability of success in drug discovery and development - from target to biomarkers
Kola, I
Hazuda, D
[J]. CURRENT OPINION IN BIOTECHNOLOGY, 2005, 16 (06) : 644 - 646
[44] Innovation Experiences from Africa-Led Drug Discovery at the Holistic Drug Discovery and Development (H3D) Centre
Singh, Vinayak
Mambwe, Dickson
Korkor, Constance Mawunyo
Chibale, Kelly
[J]. ACS MEDICINAL CHEMISTRY LETTERS, 2022, 13 (08): : 1221 - 1230
[45] Harnessing Omics Sciences, Population Databases, and Open Innovation Models for Theranostics-Guided Drug Discovery and Development
Dove, Edward S.
Oezdemir, Vural
Joly, Yann
[J]. DRUG DEVELOPMENT RESEARCH, 2012, 73 (07) : 439 - 446
[46] Chemogenomics for drug discovery: clinical molecules from open access chemical probes
Quinlan, Robert B. A.
Brennan, Paul E.
[J]. RSC CHEMICAL BIOLOGY, 2021, 2 (03): : 759 - 795
[47] Microphysiological systems as reliable drug discovery and evaluation tools: Evolution from innovation to maturity
Moon, Hye-Ran
Surianarayanan, Nishanth
Singh, Tarun
Han, Bumsoo
[J]. BIOMICROFLUIDICS, 2023, 17 (06)
[48] Targeting protein-protein interactions with low molecular weight and short peptide modulators: insights on disease pathways and starting points for drug discovery
Trisciuzzi, Daniela
Villoutreix, Bruno O.
Siragusa, Lydia
Baroni, Massimo
Cruciani, Gabriele
Nicolotti, Orazio
[J]. EXPERT OPINION ON DRUG DISCOVERY, 2023, 18 (07) : 737 - 752
[49] Understanding and creating value from open source drug discovery for neglected tropical diseases
Allarakhia, Minna
Ajuwon, Larry
[J]. EXPERT OPINION ON DRUG DISCOVERY, 2012, 7 (08) : 643 - 657
[50] New drug candidates and innovation for HAT: from discovery to promising candidates, illustrated by oxaboroles development
Ribeill, Y.
[J]. TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2011, 16 : 19 - 19

← 1 2 3 4 5 →